Skip to main content

Managing Myeloproliferative Neoplasms with Cytoreductive Pharmacotherapy Study Guide

This guide explores the principles and practical applications of cytoreductive pharmacotherapy in the management of myeloproliferative neoplasms (MPNs). It covers the underlying rationale for reducing excessive blood cell counts, the specific risks associated with conditions like Essential Thrombocythemia (ET), Polycythemia Vera (PV), and Primary Myelofibrosis (PMF), and the mechanisms by which various medications work to control these diseases. Key therapeutic agents discussed include Hydroxyur

Save this study guide to your study set

Sign up free

Your learning path

MPN Molecular Pathogenesis

JAK-STAT Signaling Pathway

Understanding the canonical signaling axis and how its dysregulation leads to uncontrolled myeloid cell proliferation.

JAK2, CALR, and MPL Mutations

Comparing the molecular mechanisms of the three primary driver mutations: JAK2, CALR indels, and MPL point mutations.

Clinical and Diagnostic Implications

How mutation profiling informs WHO diagnostic criteria and guides precision medicine/targeted therapies like JAK inhibitors.

Clonal Evolution & High-Risk Mutations

Exploring how secondary mutations like ASXL1, SRSF2, and TP53 drive disease progression and transformation from stable MPN to AML.

Classical MPN Classification

PV, ET, and PMF Profiles

Distinguishing the three classical MPNs based on dominant lineages, clinical manifestations, and characteristic blood/marrow findings.

Differential Diagnosis & Mimickers

Learning to distinguish clonal MPNs from reactive processes (like iron deficiency) and recognizing disease progression (Post-PV MF).

Bone Marrow Microenvironment & Fibrosis

Understanding how neoplastic cells remodel the marrow niche through cytokine release (TGF-beta, PDGF) and the morphological distinction between reticulin and collagenous fibrosis.

Thrombosis and Clinical Complications

Understanding the mechanisms of hyperviscosity, platelet activation, and inflammatory states that drive arterial, venous, and microvascular thrombotic events in MPN patients.

Splenomegaly and Extramedullary Hematopoiesis

Exploring how splenomegaly leads to splenic congestion and the compensatory shift of blood cell production to the spleen and liver.

MPN Therapeutic Management

Cytoreductive Pharmacotherapy

Learning about agents like Hydroxyurea, Interferon-alpha, and Anagrelide used to reduce cell counts and mitigate thrombotic risks.

  • Hydroxyurea
  • Interferon-alpha
  • Anagrelide
  • Myeloproliferative Neoplasms
  • Cytoreduction
  • Thrombosis
  • Blood cell production
  • Apoptosis
  • Vascular occlusion
  • Quality of life

Targeted JAK Inhibition

Understanding the use of Ruxolitinib, Fedratinib, and Pacritinib to disrupt JAK-STAT signaling for symptom and splenomegaly control.

Stem Cell Transplantation

Exploring the role of Allogeneic HSCT as a curative modality for high-risk or transformed MPN cases.

Make it your own.

Keep these readings and topics in a new study set, or add them to one you already use.

Get started freeLog in